|
1
|
Tilg H and Moschen AR: Role of adiponectin
and PBEF/visfatin as regulators of inflammation: involvement in
obesity-associated diseases. Clin Sci. 114:275–288. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cappellani A, Di Vita M, Zanghi A,
Cavallaro A, Piccolo G, Veroux M, Berretta M, Malaguarnera M,
Canzonieri V and Lo Menzo E: Diet, obesity and breast cancer: an
update. Front Biosci (Schol Ed). 4:90–108. 2012. View Article : Google Scholar
|
|
3
|
Thomas CC, Wingo PA, Dolan MS, Lee NC and
Richardson LC: Endometrial cancer risk among younger, overweight
women. Obstet Gynecol. 114:22–27. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Larsson SC and Wolk A: Overweight, obesity
and risk of liver cancer: a meta-analysis of cohort studies. Br J
Cancer. 97:1005–1008. 2007.PubMed/NCBI
|
|
5
|
Dennis LK, Lowe JB, Lynch CF and Alavanja
MC: Cutaneous melanoma and obesity in the Agricultural Health
Study. Ann Epidemiol. 18:214–221. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Oita RC, Ferdinando D, Wilson S, Bunce C
and Mazzatti DJ: Visfatin induces oxidative stress in
differentiated C2C12 myotubes in an Akt- and MAPK-independent,
NFκB-dependent manner. Pflugers Arch. 459:619–630. 2010.PubMed/NCBI
|
|
7
|
Adya R, Tan BK, Punn A, Chen J and Randeva
HS: Visfatin induces human endothelial VEGF and MMP-2/9 production
via MAPK and PI3K/Akt signalling pathways: novel insights into
visfatin-induced angiogenesis. Cardiovasc Res. 78:356–365. 2008.
View Article : Google Scholar
|
|
8
|
Berndt J, Klöting N, Kralisch S, Kovacs P,
Fasshauer M, Schön MR, Stumvoll M and Blüher M: Plasma visfatin
concentrations and fat depot-specific mRNA expression in humans.
Diabetes. 54:2911–2916. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tanaka M, Nozaki M, Fukuhara A, Segawa K,
Aoki N, Matsuda M, Komuro R and Shimomura I: Visfatin is released
from 3T3-L1 adipocytes via a non-classical pathway. Biochem Biophys
Res Commun. 359:194–201. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Garten A, Petzold S, Barnikol-Oettler A,
Körner A, Thasler WE, Kratzsch J, Kiess W and Gebhardt R:
Nicotinamide phosphoribosyltransferase (NAMPT/PBEF/visfatin) is
constitutively released from human hepatocytes. Biochem Biophys Res
Commun. 391:376–381. 2010. View Article : Google Scholar
|
|
11
|
Friebe D, Neef M, Kratzsch J, Erbs S,
Dittrich K, Garten A, Petzold-Quinque S, Blüher S, Reinehr T,
Stumvoll M, Blüher M, Kiess W and Körner A: Leucocytes are a major
source of circulating nicotinamide phosphoribosyltransferase
(NAMPT)/pre-B cell colony (PBEF)/visfatin linking obesity and
inflammation in humans. Diabetologia. 12:1200–1211. 2011.
|
|
12
|
Laudes M, Oberhauser F, Schulte DM, Freude
S, Bilkovski R, Mauer J, Rappl G, Abken H, Hahn M, Schulz O and
Krone W: Visfatin/PBEF/Nampt and resistin expressions in
circulating blood monocytes are differentially related to obesity
and type 2 diabetes in humans. Horm Metab Res. 42:268–273. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dahl TB, Yndestad A, Skjelland M, Øie E,
Dahl A, Michelsen A, Damås JK, Tunheim SH, Ueland T, Smith C, Bendz
B, Tonstad S, Gullestad L, Frøland SS, Krohg-Sørensen K, Russell D,
Aukrust P and Halvorsen B: Increased expression of visfatin in
macrophages of human unstable carotid and coronary atherosclerosis:
possible role in inflammation and plaque destabilization.
Circulation. 115:972–980. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sommer G, Garten A, Petzold S,
Beck-Sickinger AG, Blüher M, Stumvoll M and Fasshauer M:
Visfatin/PBEF/Nampt: structure, regulation and potential function
of a novel adipokine. Clin Sci. 115:13–23. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Dahl TB, Holm S, Aukrust P and Halvorsen
B: Visfatin/NAMPT: a multifaceted molecule with diverse roles in
physiology and pathophysiology. Annu Rev Nutr. 32:229–243. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Moschen AR, Kaser A, Enrich B, Mosheimer
B, Theurl M, Niederegger H and Tilg H: Visfatin, an adipocytokine
with proinflammatory and immunomodulating properties. J Immunol.
178:1748–1758. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fukuhara A, Matsuda M, Nishizawa M, Segawa
K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T,
Murakami H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, Kihara S,
Yamashita S, Makishima M, Funahashi T, Yamanaka S, Hiramatsu R,
Matsuzawa Y and Shimomura I: Visfatin: a protein secreted by
visceral fat that mimics the effects of insulin. Science.
307:426–430. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Imai S: Nicotinamide
phosphoribosyltransferase (Nampt): a link between NAD biology,
metabolism, and diseases. Curr Pharm Des. 15:20–28. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shackelford RE, Bui MM, Coppola D and
Hakam A: Over-expression of nicotinamide phosphoribosyltransferase
in ovarian cancers. Int J Clin Exp Pathol. 3:522–527.
2010.PubMed/NCBI
|
|
20
|
Reddy PS, Umesh S, Thota B, Tandon A,
Pandey P, Hegde AS, Balasubramaniam A, Chandramouli BA, Santosh V,
Rao MR, Kondaiah P and Somasundaram K: PBEF1/NAmPRTase/Visfatin: a
potential malignant astrocytoma/glioblastoma serum marker with
prognostic value. Cancer Biol Ther. 7:663–668. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Patel ST, Mistry T, Brown JE, Digby JE,
Adya R, Desai KM and Randeva HS: A novel role for the adipokine
visfatin/pre-B cell colony-enhancing factor 1 in prostate
carcinogenesis. Peptides. 31:51–57. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Park SH, Ozden O, Jiang H, Cha YI,
Pennington JD, Aykin-Burns N, Spitz DR, Gius D and Kim HS: Sirt3,
mitochondrial ROS, ageing, and carcinogenesis. Int J Mol Sci.
12:6226–6239. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kong W, Kuester RK, Gallegos A and Sipes
IG: Induction of DNA damage in human urothelial cells by the
brominated flame retardant 2,2-bis(bromomethyl)-1,3-propanediol:
role of oxidative stress. Toxicology. 290:271–277. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Angeli JP, Garcia CC, Sena F, Freitas FP,
Miyamoto S, Medeiros MH and Di Mascio P: Lipid
hydroperoxide-induced and hemoglobin-enhanced oxidative damage to
colon cancer cells. Free Radic Biol Med. 51:503–515. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hegde ML, Hazra TK and Mitra S: Early
steps in the DNA base excision/single-strand interruption repair
pathway in mammalian cells. Cell Res. 18:27–47. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Trachootham D, Alexandre J and Huang P:
Targeting cancer cells by ROS-mediated mechanisms: a radical
therapeutic approach? Nat Rev Drug Discov. 8:579–591. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kramer-Marek G, Serpa C, Szurko A, Widel
M, Sochanik A, Snietura M, Kus P, Nunes RM, Arnaut LG and Ratuszna
A: Spectroscopic properties and photodynamic effects of new
lipophilic porphyrin derivatives: efficacy, localisation and cell
death pathways. J Photochem Photobiol B. 84:1–14. 2006. View Article : Google Scholar
|
|
28
|
Paglia DE and Valentine WN: Studies on the
quantitative and qualitative characterization of erythrocyte
glutathione peroxidase. J Lab Clin Med. 70:158–169. 1967.PubMed/NCBI
|
|
29
|
Paoletti F and Mocali A: Determination of
superoxide dismutase activity by purely chemical system based on
NAD(P)H oxidation. Methods Enzymol. 186:209–220. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Aebi H: Catalase in vitro. Methods
Enzymol. 105:121–126. 1984. View Article : Google Scholar
|
|
31
|
Placer ZA, Cushman LL and Johnson BC:
Estimation of product of lipid peroxidation (malonyl dialdehyde) in
biochemical systems. Anal Biochem. 16:359–364. 1966. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Olive PL and Banáth JP: Detection of DNA
double-strand breaks through the cell cycle after exposure to
X-rays, bleomycin, etoposide and 125IdUrd. Int J Radiat
Biol. 64:349–356. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Turrens JF: Mitochondrial formation of
reactive oxygen species. J Physiol. 552:335–344. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Polaniak R, Bułdak RJ, Karoń M, Birkner K,
Kukla M, Zwirska-Korczala K and Birkner E: Influence of an
extremely low frequency magnetic field (ELF-EMF) on antioxidative
vitamin E properties in AT478 murine squamous cell carcinoma
culture in vitro. Int J Toxicol. 29:221–230. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Samuels BL, Murray JL, Cohen MB, Safa AR,
Sinha BK, Townsend AJ, Beckett MA and Weichselbaum RR: Increased
glutathione peroxidase activity in a human sarcoma cell line with
inherent doxorubicin resistance. Cancer Res. 51:521–527.
1991.PubMed/NCBI
|
|
36
|
Lenehan PF, Gutiérrez PL, Wagner JL, Milak
N, Fisher GR and Ross DD: Resistance to oxidants associated with
elevated catalase activity in HL-60 leukemia cells that overexpress
multidrug-resistance protein does not contribute to the resistance
to daunorubicin manifested by these cells. Cancer Chemother
Pharmacol. 35:377–386. 1995. View Article : Google Scholar
|
|
37
|
Gaweł S, Wardas M, Niedworok E and Wardas
P: Malondialdehyde (MDA) as a lipid peroxidation marker. Wiad Lek.
57:453–455. 2004.
|
|
38
|
Wang P, Xu TY, Guan YF, Su DF, Fan GR and
Miao CY: Perivascular adipose tissue-derived visfatin is a vascular
smooth muscle cell growth factor: role of nicotinamide
mononucleotide. Cardiovasc Res. 81:370–380. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Xie H, Tang SY, Luo XH, Huang J, Cui RR,
Yuan LQ, Zhou HD, Wu XP and Liao EY: Insulin-like effects of
visfatin on human osteoblasts. Calcif Tissue Int. 80:201–210. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Haider DG, Schindler K, Schaller G, Prager
G, Wolzt M and Ludvik B: Increased plasma visfatin concentrations
in morbidly obese subjects are reduced after gastric banding. J
Clin Endocrinol Metab. 91:1578–1581. 2006. View Article : Google Scholar
|
|
41
|
Revollo JR, Körner A, Mills KF, Satoh A,
Wang T, Garten A, Dasgupta B, Sasaki Y, Wolberger C, Townsend RR,
Milbrandt J, Kiess W and Imai S: Nampt/PBEF/Visfatin regulates
insulin secretion in beta cells as a systemic NAD biosynthetic
enzyme. Cell Metab. 6:363–375. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kim SR, Bae YH, Bae SK, Choi KS, Yoon KH
and Koo TH: Visfatin enhances ICAM-1 and VCAM-1 expression through
ROS-dependent NF-kappaB activation in endothelial cells. Biochim
Biophys Acta. 1783:886–895. 2008. View Article : Google Scholar : PubMed/NCBI
|
